NRAS and melanoma: In the setting of stage III disease, Ellerhorst et al. reported no difference in survival between mutant (BRAF and NRAS) and wild-type melanomas; however, in this study the mutation pattern was only obtained from the primary site and metastases were not sequenced [85].